Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

HPV16 RG1 VLP Vaccine

Phase 1Vaccine

NNational Cancer Institute (NCI)

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Human Papillomavirus-Related CarcinomaRecruiting

Human Papillomavirus-Related CarcinomaPhase 1

Recruiting

Timeline

Expected Milestones

Q3 2028

Phase 1Recruiting

Human Papillomavirus-Related Carcinoma

NCT05985681

Clinical

Trials by Indication[1]

Human Papillomavirus-Related Carcinoma1 trial

A Dose Escalation Phase I Trial of the Safety and Immunogenicity of RG1-VLP, A Candidate Broadly Protective Vaccine for the Prevention of HPV-Associated Cancer

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT05985681·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for HPV16 RG1 VLP Vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HPV16 RG1 VLP Vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HPV16 RG1 VLP Vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 1[1]
Company: NNational Cancer Institute (NCI)

Related News